{"id":"NCT00358501","sponsor":"Jazz Pharmaceuticals","briefTitle":"Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients","officialTitle":"Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-07","primaryCompletion":"2008-09","completion":"2015-03","firstPosted":"2006-08-01","resultsPosted":"2017-01-30","lastUpdate":"2017-01-30"},"enrollment":134,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Severe Hepatic Veno-Occlusive Disease"],"interventions":[{"type":"DRUG","name":"Defibrotide","otherNames":[]}],"arms":[{"label":"Defibrotide","type":"EXPERIMENTAL"},{"label":"Historical Control","type":"NO_INTERVENTION"}],"summary":"The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of veno-occlusive disease (VOD) through the analysis of blood samples.","primaryOutcome":{"measure":"Survival at Day+100 Following Hematopoietic Stem Cell Transplant","timeFrame":"Day+100 post hematopoietic stem cell transplant","effectByArm":[{"arm":"Defibrotide","deltaMin":38.2,"sd":null},{"arm":"Historical Control","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":8},"locations":{"siteCount":25,"countries":["United States","Canada"]},"refs":{"pmids":["12393437","26825712"],"seeAlso":["http://www.gentium.com/Defibrotide.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":80,"n":102},"commonTop":["Hypotension","Diarrhea","Vomiting","Pyrexia","Epistaxis"]}}